Bristol-Myers Squibb Co (LTS:0R1F)
$ 59.4 -0.61 (-1.02%) Market Cap: 119.70 Bil Enterprise Value: 163.01 Bil PE Ratio: 0 PB Ratio: 6.98 GF Score: 82/100

Bristol-Myers Squibb Co at Guggenheim Healthcare Talks: Targeted Protein Degradation Day (Virtual) - Fireside Chat Transcript

Mar 16, 2022 / 02:15PM GMT
Release Date Price: $69.8 (+0.77%)
Michael Werner Schmidt
Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MD

All right. Hello, and welcome. My name is Michael Schmidt. I'm a senior biotech analyst with Guggenheim Securities. I'm joined today by my colleague, Seamus Fernandez, our pharma analyst. And we're super excited to be hosting Bristol-Myers Squibb today at our Targeted Protein Degradation Conference.

With us today, we have Rupert Vessey. Rupert, I'm just going to -- welcome. Thanks for joining us. And I'm just going to let you introduce yourself, maybe just briefly mention your background and your current role at Bristol.

Rupert Vessey
Bristol-Myers Squibb Company - Executive VP and President of Research & Early Development

Thanks, Michael. It's great to be here. I'm Rupert Vessey. I'm President of Research and Early Development at Bristol-Myers Squibb. I'm a physician scientist by background, and I've been working in the industry for about 25 years in a whole range of different aspects of discovery, early development and translational medicine.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot